Risperidone, marketed under the trade name RISPERDAL®, is an atypical antipsychotic medication that was first approved by the US Food and Drug Administration (FDA) on December 29, 1993.

Innovent Reveals Initial Subject Receives Dose in Australian Phase 1 Trial for IBI3002 (a dual-action antibody targeting IL-4Rα and TSLP).

Diltiazem,sold under the brand name Cardizem among others, is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist).

Biocon Biologics, a fully owned arm of Biocon Ltd and a global player in biosimilars, announced today a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson.

Levofloxacin is an effective synthetic antibiotic for treating various bacterial infections, including those affecting the respiratory and urinary tracts, skin, soft tissues, and prostate.

FDA Grants ARTHEx Biotech Authorization to Start Early-Stage Clinical Study for ATX-01 in Treating Myotonic Dystrophy (DM1) under the ArthemiR™ Project.

Sumatriptan is a small molecule drug and developed by GSK. Its first approved in 1996 in the USA.

Ironwood Pharma reveals encouraging initial findings from an international Phase III study of Apraglutide, a weekly treatment for Short Bowel Syndrome leading to Intestinal Failure in adults.

Modafinil, a minuscule molecular compound marketed as PROVIGIL, received its initial approval in 1992.

ImmPACT Bio Receives $8M from CIRM for Early-Stage Trial of Novel Dual-Target CAR T-Cell Treatment IMPT-514, Aimed at Tough-to-Treat Lupus Kidney Disease and Widespread Lupus Conditions.

Gastric Cancer (GC) is a deadly global malignancy with over 1 million new cases in 2022, resulting in 783,000 deaths.

Paroxetine, a small molecule drug, is a serotonin reuptake inhibitors (SSRIs) .